We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.875 | 2.75 | 3.00 | 2.975 | 2.875 | 2.875 | 320,409 | 08:00:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.19 | 136.8M |
From May 2019 to May 2024
TIDMAGY
RNS Number : 7390T
Allergy Therapeutics PLC
08 October 2014
8 October 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Directorate Change
Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces that Alejandro Esteban Weinstein Manieu has stepped down from the Board with immediate effect.
Peter Jensen, Chairman of the Board, said: "Alejandro has made an enormous contribution to the development of Allergy Therapeutics since his involvement in 2009 and I would like to take this opportunity to thank him for his valuable guidance and support."
For further information
Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director Peel Hunt LLP +44 (0) 20 7418 8900 James Steel Clare Terlouw FTI Consulting +44 (0) 20 3727 1000 Simon Conway Victoria Foster Mitchell
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUGGWCUUPCUQR
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
